Atypical protein kinase C phosphorylates IKKαβ in transformed non-malignant and malignant prostate cell survival

Cancer Letters

Volumn 270, Issue 2, 2008, Pages 302-311

  Win, Hla Y ^a   Acevedo Duncan, Mildred ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cell survival; NF B; Prostate cancer; Protein kinase C ; Protein kinase C

Indexed keywords

ATYPICAL PROTEIN KINASE C IOTA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE C IOTA; PROTEIN KINASE C ZETA; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS MEMBRANE; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TRANSPORT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANDROGENS; APOPTOSIS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; I-KAPPA B KINASE; ISOENZYMES; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE C; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 52149112088     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.05.023     Document Type: Article

References (60)

1. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 (2001) 34-35
2. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Ronsenfeld M.G., and Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10 (2004) 33-39
3. Huggins C., and Hodges C.V. Studies on prostatic cancer: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of prostate. Cancer Res. 1 (1941) 293-297
4. Gregory C.W., Johnson R.T., Mohler J.L., French F.S., and Wilson E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61 (2001) 2892-2893
5. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., Keer H.N., and Balk S.P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332 (1995) 393-1398
6. Gleave M., Tolcher A., Miyake H., Nelson C., Brown B., Beraldi E., and Goldie J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res. 5 (1999) 2891-2898
7. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W.K., Hsieh J.T., Tu S.M., and Cambell M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52 (1992) 280-285
8. Knapp L.T., and Klann E. Superoxide-induced stimulation of protein kinase C via thiol modification and modulation of zinc content. J. Biol. Chem. 275 (2000) 24136-24145
9. Nishizuka Y. Studies and perspectives of protein kinase C. Science 233 (1986) 305-312
10. Roberson E.D., English J.D., and Sweatt J.D. A biochemist's view of long-term potentiation. Learn. Mem. 3 (1996) 1-24
11. Cornfor P., Evans J., Dodson A., Parsons K., Woolfenden A., Neoptolemos J., and Foster C.S. Protein kinase C isozymes patterns characteristically modulated in early prostate cancer. Am. J. Pathol. 154 (1999) 37-144
12. Powell C.T., Birttis N.J., Stec D., Hug H., W Heston W.D., and Fair W.R. Persistent membrane translocation of protein kinase C α during 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ. 7 (1996) 419-428
13. Gonzalex-Guerrico A.M., Meshki J., Xiao L., Benavides F., Conti C.J., and Kazanietz M.G. Molecular mechanisms of protein kinase C-induced apoptosis in prostate cancer cells. J. Biochem. Mol. Biol. 38 (2005) 639-645
14. Garcia-Bermejo M.L., Leskow F.C., Fujii T., Wang Q., Blumberg P.M., Ohba M., Kuroki T., Han K., Lee J., Marquez V.E., and Kazanietz M.G. Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKC-α. J. Biol. Chem. 244 (2002) 645-655
15. Stewart J.R., and O'Brian C.A. Protein kinase C-α mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Mol. Cancer Ther. 4 (2005) 726-732
16. Shih A., Zhang S., Cao H.J., Boswell S., Wu Y.H., Tang H.Y., Lennartz M.R., Davis F.B., Davis P.J., and Lin H.Y. Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-α. Mol. Cancer Ther. 3 (2004) 1355-1363
17. Lamm M.L., Long D.D., Goodwin S.M., and Lee C. Transforming growth factor-beta I inhibits membrane association of protein kinase C alpha in a human prostate cancer cell line PC3. Endocrinology 138 (1997) 4657-4664
18. Oxley J.E., Winkler M.H., Gillatt D.A., and Peat D.S. Her-2/neu oncogene amplification in clinically localized prostate cancer. J. Clin. Pathol. 55 (2002) 18-120
19. Lahn M., Sundell K., Gleave M., Lada F., Su C., Lit S., Ma D., Paterson B.M., and Bumol T.F. Protein kinase C-α in prostate cancer. Br. J. Urol. 93 (2004) 1076-7081
20. Dean N.M., McKay R., Condon T.P., and Bennett C.F. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (CAM-1) mRNA by phorbol-esters. J. Biol. Chem. 269 (1994) 16416-16424
21. Davies A.M., Gandara D., Lara P., Mack P., Lau D., and Gumerlock P. Antisense oligonucleotides in the treatment of NSCLC. Clin. Lung Cancer 4 (2003) S68-S73
22. Fuji T., Garcia-Bermejo M.L., Bernabo J.L., Camano J., Ohba M., Kuroki T., Li L., Yuspa S.H., and Kazanietz M.G. Involvement of protein kinase C (PKCδ) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. J. Biol. Chem. 275 (2000) 7574-7582
23. Kharait S., Dhir R., Lauffenburger D., and Wells A. Protein kinase Cδ signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem. Biophys. Res. Commun. 343 (2006) 848-856
24. Rosenberg M., and Ravid S. Protein kinase Cγ regulates myosin IIB phosphorylation, cellular localization, and filament assembly. Mol. Biol. Cell 17 (2006) 1364-1374
25. Wu D., Thakore C.U., Wescott G.G., McCubrey J.A., and Terrian D.M. Integrin signaling links protein kinase Cε to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene 23 (2004) 5689-8672
26. Rusnak J.M., and Lazo J.S. Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. Exp. Cell Res. 224 (1996) 189-199
27. Rao P.S., Jaggi M., Smith D.J., Hemstreet G.P., and Balaji K.C. Metallothionein 2A interacts with the kinase domain of PKCμ in prostate cancer. Biochem. Biophys. Res. Commun. 310 (2003) 1032-1038
28. Jaggi M., Rao P.S., Smith D.J., Hemstreet G.P., and Balji K.L. Protein kinase C μ is down-regulated in androgen-independent prostate cancer. Biochem. Biophys. Res. Commun. 307 (2003) 254-260
29. Inoue T., Yoshida T., Shimizu Y., Kobayashi T., Yamasaki T., Toda Y., Segawa T., Kamoto T., Nakamura E., and Ogawa O. Requirement of androgen-dependent activation of protein kinase Cζ for androgen-dependent cell proliferation in LNCaP cells and its roles in transition to androgen-independent cells. Mol. Endocrinol. 20 (2006) 3053-3069
30. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., Castle V.P., and Opipari Jr. A.W. NF-κB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J. Biol. Chem. 276 (2001) 48921-48929
31. De Vente J., Kiley S., Garris T., Bryant W., Hooker J., and Posekany K. Phorbol ester treatment of U937 cells with altered protein kinase C content and distribution induces cell death rather than differentiation. Cell Growth Differ. 6 (1995) 371-382
32. Ways D.K., Posekany K., De Vente J., Garris T., Chen J., and Hooker J. Overexpression of protein kinase C-zeta stimulates leukemic cell differentiation. Cell Growth Differ. 11 (1994) 1195-1203
33. Murray N.R., and Fields A.P. Atypical protein kinase C iota protects human leukemia cells against drug-induced apoptosis. J. Biol. Chem. 272 (1997) 27521-27524
34. Lu Y., Jamieson L., Brasier A.R., and Fields A.P. NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival. Oncogene 20 (2001) 4777-4792
35. Acevedo-Duncan M., Patel R., Whelan S., and Bicaku E. Human glioma PKC-ι and PKC-βΙΙ phosphorylate cyclin-dependent kinase activating kinase during the cell cycle. Cell Proliferat. 35 (2002) 23-36
36. Bicaku E., Patel R., and Acevedo-Duncan M. Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-iota in human glioma cells. Tissue Cell 34 (2005) 53-58
37. Chuang S.E., Y Yeh P., Lu Y.S., Lai G.M., Liao C.M., Gaio M., and Cheng A.L. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB) and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem. Pharmacol. 63 (2002) 1709-1716
38. Yamamoto Y., and Gaynor R.B. IκB kinases: key regulators of the NF-κB pathway. Trends Biochem. Sci. 29 (2004) 72-79
39. Flynn J.V., Ramanitharan A., Moparty K., Davis R., Sikka S., Agrawal K.C., and Abdel-Mageed S.B. Adenovirus-mediated inhibition of NF-κB confers chemo-sensitization and apoptosis in prostate cancer cells. Int. J. Oncol. 23 (2003) 323-371
40. Hsu H., Huang J., Shu H.B., Baichwal V., and Goeddel D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4 (1996) 387-396
41. Sanz L., Sanchez P., Lallena M.J., Diaz-Meco M.T., and Moscat J. The interaction of p62 with RIP links the atypical PKCs to NF-κB activation. EMBO J. 18 (1999) 3044-3053
42. Delhase M., Hayakawa M., Chen Y., and Karin M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 284 (1999) 309-313
43. Brown K., Gerstberger S., Carlson L., Franzoso G., and Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal induced phosphorylation. Science 267 (1995) 1485-1488
44. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
45. Chopra D.P., Menard R.E., Januszewski J., and Mattingly R.R. TNF-α-mediated apoptosis in normal prostate epithelial cells and tumor cell lines. Cancer Lett. 20 (2004) 145-154
46. Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J., and Budunova I.V. The role of IKK in constitutive activation of NF-κB transcription factor in prostate carcinoma cells. J. Cell Sci. 151 (2002) 141-151
47. Krappmann D., Wulczyn F.G., and Scheidereit C. Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo. EMBO J. 15 (1996) 6716-6726
48. Suh J., Rayvandi F., Edelstein L.C., Amenta P.S., Zong W., Gelinas C., and Rabson A.B. Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate 52 (2002) 183-200
49. Grossman D., Kim P.J., Blanc-Brude O.P., Brash D.E., Tognin S., Marchisio P.C., and Altieri D.C. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 108 (2001) 991-999
50. Palayoor S.T., Youmell M.Y., Calderwood S.K., Coleman C.N., and Price B.D. Constitutive activation of IκB kinase and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18 (1999) 7389-7394
51. Shukla S., MacLeannan G.T., Fu P., Patel J., Marengo S.R., Resnick M.I., and Gupta S. Nuclear factor-kB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 6 (2004) 390-400
52. Sweeney C., Li L., Shanmugam R., Bhat-Nakshatri P., Jayaprakasan V., Baldridge L.A., Gardner T., Smith M., Nakshatri H., and Chen L. Nuclear factor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res. 10 (2004) 5501-5507
53. Leitges M., Sanz L., Martin P., Duran A., Braun U., Garcia J.G., Camacho F., Diaz-Meco M.T., Rennert P.D., and Moscat J. Targeted Disruption of the ζPKC gene results in the impairment of the NF-κB pathway. Mol. Cell 8 (2001) 771-780
54. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., and Baldwin A.S. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and cIAP1 and cIAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
55. Wu M.X., Ao Z., Prasad K.V., Wu R., and Scholossman S.F. IEX-1L, an apoptosis inhibitor involved in NF-κB mediated cell survival. Science 281 (1998) 998-1001
56. Bello D., Webber M.M., Kleinman H.K., Wartinger D.D., and Rhim J.S. Androgen responsive adult human prostate epithelial cell lines immortalized by papillomavirus 18. Carcinogenesis 18 (1997) 1215-1223
57. Lee F.S., Peters R.T., Dang L.C., and Maniatis T T. MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. PNAS 95 (1998) 3792-3797
58. Baeuerle P.A., and Baltimore D. NF-kappa B: ten years after. Cell 87 (1996) 13-20
59. Catz S.D., and Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20 (2001) 7342-7351
60. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308